Immunosuppressive networks in the tumour environment and their therapeutic relevance

It is well known that many tumours are potentially immunogenic, as corroborated by the presence of tumour-specific immune responses in vivo. Nonetheless, spontaneous clearance of established tumours by endogenous immune mechanisms is rare. Therefore, the focus of most cancer immunotherapies is to supplement essential immunogenic elements to boost tumour-specific immunity. Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact that tumours develop diverse strategies that escape tumour-specific immunity.

[1]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[2]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[3]  P. Black,et al.  Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. , 2000, Cancer research.

[4]  R. Offringa,et al.  Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine , 2001, The Journal of experimental medicine.

[5]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[6]  S. Jozefowski,et al.  Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved. , 2003, International immunopharmacology.

[7]  R. Offringa,et al.  Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 , 2004, The Journal of Immunology.

[8]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[9]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[10]  Lin Zhang,et al.  Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004, Nature Medicine.

[11]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[12]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[13]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[14]  E. Shevach Fatal attraction: tumors beckon regulatory T cells , 2004, Nature Medicine.

[15]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[16]  J. Blay,et al.  Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.

[17]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[18]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[19]  N. Mitsiades,et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.

[20]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[21]  R. Steinman,et al.  Direct Expansion of Functional CD25+ CD4+ Regulatory T Cells by Antigen-processing Dendritic Cells , 2003, The Journal of experimental medicine.

[22]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[23]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[24]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[25]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[26]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[27]  F. Foss A Novel Fusion Toxin Therapy for Lymphoma , 2000 .

[28]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.

[29]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[30]  D. Klinman Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[31]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Greenberg,et al.  Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses , 2002, Nature Reviews Cancer.

[33]  C. Atkinson,et al.  Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. , 1998, The Journal of urology.

[34]  C. Dong,et al.  B7S1, a novel B7 family member that negatively regulates T cell activation. , 2003, Immunity.

[35]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[36]  J. Petersen,et al.  Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. , 1999, Immunity.

[37]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[38]  Scott N. Mueller,et al.  Rapid Cytotoxic T Lymphocyte Activation Occurs in the Draining Lymph Nodes After Cutaneous Herpes Simplex Virus Infection as a Result of Early Antigen Presentation and Not the Presence of Virus , 2002, The Journal of experimental medicine.

[39]  G. Zhu,et al.  B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. , 2003, Immunity.

[40]  M. Noris,et al.  Natural versus adaptive regulatory T cells. , 2005, Contributions to nephrology.

[41]  Eli Gilboa,et al.  The promise of cancer vaccines , 2004, Nature Reviews Cancer.

[42]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[43]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[45]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[46]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[47]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Atkinson,et al.  Minimal recruitment and activation of dendritic cells within renal cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[50]  S. Hussain,et al.  CD4+CD25+ Regulatory T Cells That Secrete TGFβ and IL-10 Are Preferentially Induced by a Vaccine Vector , 2004, Journal of immunotherapy.

[51]  Andy Smith Mapping the way , 2002, Trends in Neurosciences.

[52]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[53]  M. Smyth,et al.  Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.

[54]  P. Kalinski,et al.  Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. , 1998, Journal of immunology.

[55]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[56]  Lei Shen,et al.  Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity , 2004, Nature Biotechnology.

[57]  Lieve Moons,et al.  CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.

[58]  A. Frey,et al.  Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide1 , 2001, The Journal of Immunology.

[59]  鬼塚 正三郎 Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody , 1999 .

[60]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[61]  H. Shinohara,et al.  Prognostic value of tumor‐infiltrating dendritic cells expressing CD83 in human breast carcinomas , 2003, International journal of cancer.

[62]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[63]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[64]  J. Ochoa,et al.  l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1 , 2003, The Journal of Immunology.

[65]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[66]  V. Cerundolo,et al.  Plasmacytoid dendritic cells prime IFN‐γ‐secreting melanoma‐specific CD8 lymphocytes and are found in primary melanoma lesions , 2003, European journal of immunology.

[67]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[68]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[69]  T. Giese,et al.  Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. , 2003, Cancer research.

[70]  Nina Bhardwaj,et al.  Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[71]  K. Black,et al.  Induction of a CD4+ T Regulatory Type 1 Response by Cyclooxygenase-2-Overexpressing Glioma1 , 2004, The Journal of Immunology.

[72]  Youjin Lee,et al.  Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.

[73]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[74]  T. Shono,et al.  Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. , 2001, Cancer research.

[75]  A. Castonguay,et al.  Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. , 1997, Carcinogenesis.

[76]  Angela Panoskaltsis-Mortari,et al.  Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.

[77]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[78]  S. Adams,et al.  Manipulating dendritic cell biology for the active immunotherapy of cancer. , 2004, Blood.

[79]  Y. Belkaid,et al.  Role for CD4+ CD25+ Regulatory T Cells in Reactivation of Persistent Leishmaniasis and Control of Concomitant Immunity , 2004, The Journal of experimental medicine.

[80]  J. Banchereau,et al.  In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas , 1999, The Journal of experimental medicine.

[81]  Jeffrey A. Bluestone,et al.  Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells , 2003, Nature Reviews Immunology.

[82]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[83]  R. Steinman,et al.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.

[84]  Y. Kawahito,et al.  Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.

[85]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[86]  K. Seibert,et al.  The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.

[87]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[88]  B. Foster,et al.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[89]  S. Mehrotra,et al.  Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. , 2004, Human immunology.

[90]  Lieping Chen,et al.  Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. , 2004, The Journal of clinical investigation.

[91]  A. Raz,et al.  Indomethacin Inhibits the Accumulation of Tumor Cells in Mouse Lungs and Subsequent Growth of Lung Metastases , 2000, Chemotherapy.

[92]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[93]  H. Adami,et al.  Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.

[94]  Christopher Anderson,et al.  More questions than answers , 1991, Nature.

[95]  M. Gilliet,et al.  Generation of Human CD8 T Regulatory Cells by CD40 Ligand–activated Plasmacytoid Dendritic Cells , 2002, The Journal of experimental medicine.

[96]  A. Krieg CpG motifs: the active ingredient in bacterial extracts? , 2003, Nature Medicine.

[97]  A. Enk,et al.  Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells , 2000, The Journal of experimental medicine.

[98]  Susan M. Kaech,et al.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.

[99]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[100]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[101]  Shu-Hsia Chen,et al.  Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.

[102]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.

[103]  P. Hwu,et al.  The immunotherapy of patients with ovarian cancer. , 2002, Journal of immunotherapy.

[104]  Mapping the way , 2002, Trends in Cognitive Sciences.

[105]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[106]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[107]  C. Meijer,et al.  Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.

[108]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[109]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[110]  E. Pamer,et al.  CD8 T cell responses to infectious pathogens. , 2003, Annual review of immunology.

[111]  M. Feuerer,et al.  Bone marrow as a priming site for T-cell responses to blood-borne antigen , 2003, Nature Medicine.

[112]  V. Cerundolo,et al.  The use of HLA class I tetramers to design a vaccination strategy for melanoma patients , 2002, Immunological reviews.

[113]  M. Jenkins,et al.  Antigen presentation to naive CD4 T cells in the lymph node , 2003, Nature Immunology.

[114]  V. Cerundolo,et al.  Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.

[115]  L. Karabon,et al.  IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity , 2000, British Journal of Cancer.

[116]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Ralph S Freedman,et al.  Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC) , 2004, Journal of Translational Medicine.

[118]  Leonard C. Harrison,et al.  Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity , 2003, Nature Reviews Immunology.

[119]  H. Choy,et al.  Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.

[120]  Lieping Chen Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[121]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[122]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[123]  P. Borrow,et al.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.

[124]  P. Carmeliet,et al.  Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.

[125]  F. Sallusto,et al.  The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. , 2001, Current opinion in immunology.

[126]  Stephen P. Schoenberger,et al.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.

[127]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[128]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[129]  T. Tüting,et al.  Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.

[130]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[131]  M. Lotze,et al.  Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. , 2001, Cancer research.

[132]  S. H. van der Burg,et al.  Strategies for immunotherapy of cancer. , 2000, Advances in immunology.

[133]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[134]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[135]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[136]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[137]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[138]  T. Luger,et al.  Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. , 1999, Journal of immunology.

[139]  F. Foss DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. , 2000, Clinical lymphoma.

[140]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[141]  P. Loke,et al.  B7x: A widely expressed B7 family member that inhibits T cell activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[142]  D. Schmitt,et al.  Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their Apoptosis , 2003, The Journal of Immunology.

[143]  J J Padgett,et al.  A renewed sense of self. , 1994, Journal of psychosocial nursing and mental health services.

[144]  V. Bronte,et al.  Tumor-induced immune dysfunctions caused by myeloid suppressor cells. , 2001, Journal of immunotherapy.

[145]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[146]  G. Zhu,et al.  B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. , 2001, Blood.

[147]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[148]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.